WO2013024157A3 - Combinations of anti -hcv - entry factor antibodies, protein kinase inhibitors or alisporivir for the treatment and the prevention of hcv infection - Google Patents

Combinations of anti -hcv - entry factor antibodies, protein kinase inhibitors or alisporivir for the treatment and the prevention of hcv infection Download PDF

Info

Publication number
WO2013024157A3
WO2013024157A3 PCT/EP2012/066108 EP2012066108W WO2013024157A3 WO 2013024157 A3 WO2013024157 A3 WO 2013024157A3 EP 2012066108 W EP2012066108 W EP 2012066108W WO 2013024157 A3 WO2013024157 A3 WO 2013024157A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
combinations
alisporivir
protein kinase
prevention
Prior art date
Application number
PCT/EP2012/066108
Other languages
French (fr)
Other versions
WO2013024157A2 (en
Inventor
Thomas Baumert
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Universiτε De Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Universiτε De Strasbourg filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2013024157A2 publication Critical patent/WO2013024157A2/en
Publication of WO2013024157A3 publication Critical patent/WO2013024157A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides combinations for use in the treatment or the prevention of HCV infection. In particular, combinations are provided that comprise two host-targeting agents, such as for example at least one anti-HCV-entryfactor antibody and at least one protein kinase inhibitor, or at least one anti-HCV-entry factor antibody and alisporivir, or at least one protein kinase inhibitor and alisporivir, wherein the two host-targeting agents act in a highly synergistic manner to inhibit HCV entry and infection in susceptible cells. Also provided are pharmaceutical compositions and kits comprising such combinations and methods of using these compositions and kits for treating or preventing HCV infection.
PCT/EP2012/066108 2011-08-17 2012-08-17 Combinations of host targeting agents for the treatment and the prevention of hcv infection WO2013024157A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306054 2011-08-17
EP11306054.5 2011-08-17

Publications (2)

Publication Number Publication Date
WO2013024157A2 WO2013024157A2 (en) 2013-02-21
WO2013024157A3 true WO2013024157A3 (en) 2013-04-11

Family

ID=46704646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/066108 WO2013024157A2 (en) 2011-08-17 2012-08-17 Combinations of host targeting agents for the treatment and the prevention of hcv infection

Country Status (1)

Country Link
WO (1) WO2013024157A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161202A1 (en) * 2016-03-17 2017-09-21 University Of Southern California Src inhibitor to block cell surface grp78 expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110455A2 (en) * 2004-05-13 2005-11-24 Intermune, Inc. Combination therapy for treating hepatitis virus infection
WO2006005465A1 (en) * 2004-07-08 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
WO2010034812A1 (en) * 2008-09-25 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5653034A (en) 1995-05-24 1997-08-05 Trijicon, Inc. Reflex sighting device for day and night sighting
CN100391469C (en) 2000-02-14 2008-06-04 三菱制药株式会社 Remedies for hepatitis C
IL139217A0 (en) 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
AU750296B2 (en) 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
CA2425513A1 (en) 2000-10-25 2002-06-20 Vincent Agnello Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
EP1870421B1 (en) 2005-03-31 2011-08-17 Seikagaku Corporation Anti-heparan sulfate antibody, method for detection of heparan sulfate, and kit for detection of heparan sulfate
EP2016100B1 (en) 2006-05-04 2014-07-09 The Rockefeller University Hcv coreceptor and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110455A2 (en) * 2004-05-13 2005-11-24 Intermune, Inc. Combination therapy for treating hepatitis virus infection
WO2006005465A1 (en) * 2004-07-08 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
WO2010034812A1 (en) * 2008-09-25 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FLISIAK ROBERT ET AL: "The cyclophilin inhibitor Debio 025 combined with PEG IFN.alpha.2a significantly reduces viral load in treatment-naive hepatitis C patients", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 49, no. 5, 1 May 2009 (2009-05-01), pages 1460 - 1468, XP008127170, ISSN: 0270-9139, [retrieved on 20090204], DOI: 10.1002/HEP.22835 *
LUPBERGER JOACHIM ET AL: "EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy", NATURE MEDICINE, vol. 17, no. 5, May 2011 (2011-05-01), pages 589 - 595+METHOD, XP002666425, ISSN: 1078-8956 *
MEULEMAN PHILIP ET AL: "Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 48, no. 6, 1 December 2008 (2008-12-01), pages 1761 - 1768, XP002610195, ISSN: 0270-9139, DOI: 10.1002/HEP.22547 *
TANABE YOKO ET AL: "Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.", THE JOURNAL OF INFECTIOUS DISEASES 1 APR 2004 LNKD- PUBMED:15031779, vol. 189, no. 7, 1 April 2004 (2004-04-01), pages 1129 - 1139, XP002685604, ISSN: 0022-1899 *
ZEISEL MIRJAM B ET AL: "Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies", JOURNAL OF HEPATOLOGY, vol. 54, no. 3, March 2011 (2011-03-01), pages 566 - 576, XP002666426, ISSN: 0168-8278 *

Also Published As

Publication number Publication date
WO2013024157A2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
WO2014062720A3 (en) Methods of treating cancer
WO2013188813A3 (en) Novel therapeutics for brain cancer
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2015DN01197A (en)
IN2015DN01161A (en)
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
MX2023010206A (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack.
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
MX2015011898A (en) Pyrazolo compounds and uses thereof.
WO2012142498A3 (en) Mif inhibitors and their uses
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2010088368A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX2014004074A (en) Methods of treating liver conditions using notch2 antagonists.
WO2013106689A8 (en) Hcv ns3 protease inhibitors
WO2010032011A3 (en) Anti-fungal therapy
NZ730771A (en) Aurora a kinase inhibitor
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
MX2017011018A (en) Inhibition of olig2 activity.
UA115305C2 (en) Hyr1-derived compositions and methods of treatment using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12748460

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12748460

Country of ref document: EP

Kind code of ref document: A2